|
Reliance Industries Limited
|
|
POLYPROPYLENE
|
| REPOL H110FG |
HOMOPOLYMER |
| |
| Product description &
applications : |
Features
: |
|
REPOL Polypropylene H110FG is manufactured
using Unipol PP process which combines the production
efficiency of gas phase fluidized bed reactor technology
with the high activity and stereo specificity of the
SHAC catalyst system.
REPOL H110FG is recommended for use in
fibre spining operations and is pariclarly suited for
bulk continuous filaments (BCF) and fibre production
|
Repol
H110FG is designed to provide
- Good spinning characteristics
- Consistent processabillity
- Good colour stability
- High tensile properties
|
| |
| Typical properties
of Repol H110FG are as follows: |
| |
| Property |
ASTM Test
Method |
Unit |
Typical Value*. |
| Melt flow index,(230oc/2.16Kg) |
D 1238 |
g/10 min |
11.0 |
| Tensile Strength
at yield (50 mm/min ) |
D 638$ |
MPa |
35 |
| Elongation at
yield (50 mm/min ) |
D 638$ |
% |
10 |
| Flexural modulus
(1% secant) |
D 790A$ |
MPa |
1600 |
| Notched izod
impact strength (23oc) |
D 256$ |
J/m |
26 |
| Heat deflection
temperature (455 kPa) |
D 648 |
oC |
104 |
| |
|
$ : ASTM D638 Type I specimen injection
moulded and tested in accordance with ASTM D4101.
|
| |
|
Repol H110FG meets the requirements
stipulated in IS 10910-1984 on on "Specification for
Polypropylene and its copolymers for safe use in contact
with foodstuffs, pharmaceuticals, and drinking water".
Additives incorporated in this grade conform to the
positive list of constituents as prescribed in IS-10909-1984.The
grade and the additives incorporated in it also comply
with the FDA:CFR Title 21, 177.1520, Olefin polymers.
|
| |
|
REPOL is the registered trademark for
Polypropylene from Reliance Industries Limited
|
| |
|
* Typical valuesw with injection moulded
specimens, not to be taken as specification
|
|
The data, information and suggestions
contained contained herein are given purely as a guide.
Reliance Industries Limited and Reliance Group Companies
undertake no responsibility either for the results deriving
from their adoption or for possible position in apparent
contrast with existing patent rights.
|
| |
| |